GlassScriptPhysician profile
Bart Ghislain Denys
NPI 1659378685
$29,397.79
in general payments reported to CMS, 2019-2025
28 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,079 · 2021: $5,534 · 2022: $1,045 · 2023: $609 · 2024: $777 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,986.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $8,804.14 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $4,351.58 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $716.97 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $560.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $418.56 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $226.50 | 2023-2025 | Onpattro |
| Amgen INC. | $209.48 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.70 | 2020-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $118.12 | 2019-2023 | Livalo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.93 | 2020-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $88.88 | 2019-2023 | |
| Abiomed | $80.54 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $71.53 | 2021-2025 | Evkeeza |
| Amarin Pharma, INC. | $67.41 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $56.54 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $55.13 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $37.48 | 2020-2021 | |
| Itamar Medical INC | $36.94 | 2022-2023 | Watchpatone |
| Kiniksa Pharmaceuticals International, Plc | $34.10 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $32.05 | 2022-2024 | Opsumit, Uptravi |
| Ancora Heart, INC. | $32.00 | 2021 | |
| Kestra Medical Technology Services, INC. | $29.44 | 2022-2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $27.08 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.37 | 2023 | Xarelto |
| Boston Scientific Corporation | $19.18 | 2023 | |
| Impulse Dynamics (USA) INC. | $19.08 | 2022 | |
| Medtronic Vascular, INC. | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bart Denys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.